Detalles de la búsqueda
1.
Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib.
Int J Toxicol
; 42(6): 515-534, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37667445
2.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs
; 38(5): 1570-1579, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140889
3.
Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Pharm Stat
; 19(3): 276-290, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31903699
4.
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Cancer Immunol Immunother
; 68(1): 1-9, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30564889
5.
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Invest New Drugs
; 37(1): 118-126, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29995286
6.
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Liver Int
; 39(8): 1468-1477, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30963691
7.
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Br J Cancer
; 119(10): 1208-1214, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30318515
8.
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Int J Mol Sci
; 18(5)2017 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28481241
9.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-ß receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Invest New Drugs
; 33(2): 357-70, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25529192
10.
Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation.
Strahlenther Onkol
; 190(11): 1037-45, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24863573
11.
Defining a therapeutic window for the novel TGF-ß inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
Br J Clin Pharmacol
; 77(5): 796-807, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24868575
12.
Why are we failing to implement imaging studies with radiolabelled new molecular entities in early oncology drug development?
ScientificWorldJournal
; 2014: 269605, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25202719
13.
Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers.
Cancer Drug Resist
; 7: 2, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38318526
14.
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
Eur J Cancer
; 198: 113501, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38169219
15.
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFß Inhibition in Pancreatic Ductal Adenocarcinoma.
Cancer Res
; 84(1): 118-132, 2024 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738399
16.
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.
Transl Oncol
; 43: 101857, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38412661
17.
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).
Invest New Drugs
; 31(4): 1023-34, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23397500
18.
Immunotherapy for brain metastases and primary brain tumors.
Eur J Cancer
; 179: 113-120, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521332
19.
Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models.
J Exp Clin Cancer Res
; 42(1): 197, 2023 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37550785
20.
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.
Cancer Res Commun
; 3(4): 576-591, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37066023